GlassScriptPhysician profile
George A Youssef
NPI 1639381338
$9,579.20
in general payments reported to CMS, 2019-2025
29 companies · $4,233 in 2025
The $4,233 reported for 2025 was more than what 81% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $228 · 2021: $138 · 2022: $2,890 · 2023: $850 · 2024: $531 · 2025: $4,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027 · Travel and Lodging: $2,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,027.02 |
| Travel and Lodging | $2,586.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $5,571.58 | 2022-2025 | Indigo System |
| Bard Peripheral Vascular, INC. | $618.42 | 2022 | |
| Pfizer INC. | $562.50 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $305.34 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.80 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $259.08 | 2022-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $255.81 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $232.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $184.33 | 2019-2025 | Farxiga |
| Amgen INC. | $145.66 | 2019-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $98.91 | 2025 | Assure Wcd |
| W. L. Gore & Associates, INC. | $96.00 | 2021 | |
| Cardiovascular Systems INC. | $94.12 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.94 | 2020-2025 | Lifevest |
| Biocompatibles, INC. | $91.72 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $82.45 | 2023 | Impella |
| Inari Medical, INC. | $71.40 | 2022 | |
| Zoll Circulation INC | $68.45 | 2023 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Sanofi-Aventis U.S. LLC | $63.37 | 2019 | |
| Boston Scientific Corporation | $58.35 | 2023-2024 | Watchman Flx, Watchman Access System |
| Cvrx, INC. | $56.95 | 2024-2025 | Barostim Neo System |
| Philips North America LLC | $53.55 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Impulse Dynamics (USA) INC. | $47.27 | 2023 | Optimizer |
| Lantheus Medical Imaging, INC. | $42.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.36 | 2023 | |
| Cardiva Medical, INC. | $32.80 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Stryker Corporation | $22.24 | 2025 | Clottriever Bold Catheter |
| Regeneron Healthcare Solutions, INC. | $18.61 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.